AN2 Therapeutics Inc
ANTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$194.85M
Close$
$0.66
87.8% downside
Current Fair Value
87.8% downsideOvervalued by 87.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $194.85 Million |
|---|---|
| Enterprise Value | $150.53 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.16 |
| Beta | -0.99 |
| Outstanding Shares | 44,760,766 |
Return
| Return on Equity | -47.78% |
|---|---|
| Return on Assets | -44.41% |
| Return on Invested Capital | -49.37% |
Valuation & Multiples
| P/E Ratio | -5.06 |
|---|---|
| PEG | -18.96 |
| Price to Sales | - |
| Price to Book Ratio | 5.41 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -4.01 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.24
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.20
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 55.07%▼ 9.22% |
|---|---|
| Total Invested | $119.30M▲ 59.54% |
| Investors Holding | 67▲ 15.00% |
ESG Score
No data